Baxter reports positive data from long-term Advate study

Baxter has presented clinical data from a four-year outcomes registry of haemophilia A patients treated with its recombinant factor VIII treatment Advate.

Interim results from the first year of observation from the Ahead study support the clinical experience of prophylaxis treatment with Advate, finding the majority of patients on prophylaxis had fewer than two bleeding episodes per year.

Of these patients, 51 percent experienced no bleeds during one year of treatment, adding to the robust body of evidence available on the safety and efficacy of Advate in both clinical trial and real-world settings.

The data was presented as part of a wider series of sessions at the European Association for Haemophilia and Allied Disorders meeting in Brussels, Belgium.

Dr Ludwig Hantson, president of Baxter's bioscience business, said: "This data strongly supports the concept of treating prophylactically to reduce the risk of bleeding episodes, a measurable target that we continue to pursue as part of our vision of a bleed-free world."

This comes after the company received EU approval to update the product details of Advate to include phase IV clinical data last year.